AUNJEL FAUCHEUX: Open Payments
NPI 1194232330 · SLIDELL, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$849 in 49 payments from 14 companies in 2025. Trend: 2023 $1,126 · 2024 $1,869 · 2025 $849
Food & beverage: $849
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $179 |
| Lilly USA, LLC | 5 | $175 |
| ABBVIE INC. | 12 | $139 |
| GlaxoSmithKline, LLC. | 5 | $94 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Merck Sharp & Dohme LLC | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $26 |
| Abbott Laboratories | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
Products named: ZEPBOUND, VRAYLAR, Ozempic, SHINGRIX, MOUNJARO, REXULTI, Wegovy, Rybelsus.
Industry payments across LA — which companies pay providers there.
